Los Angeles Business Journal

Amgen, Merck to Collaborate on Cancer Drugs

By Business Journal Staff Wednesday, February 5, 2014

Clinical trials will begin this fall for an advanced melanoma drug developed in a collaboration of Amgen Inc. and Merck & Co. Inc.

Amgen, in Thousand Oaks, and Merck, in Whitehouse Station, N.J., are working on talimogene laherparepvec, an investigational oncolytic immunotherapy, combined with MK-3475, an investigational immunotherapy.

"Talimogene laherparepvec has shown encouraging Phase 3 clinical results as a monotherapy in patients with metastatic melanoma," said Dr. David Chang, vice president of global development at Amgen, in a prepared statement.

Shares of Amgen fell 71 cents, less than 1percent, to $115.07 on the Nasdaq.